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Abstract
Background: Given the growing number of ocular hypotensive medications available, it is important to be able to 
predict a positive response to therapy. The purpose of the present study was to identify predictors of an additional 10% 
intraocular pressure (IOP) reduction after 12 weeks of treatment with latanoprost/timolol fixed combination (FC) in 
patients requiring a change in their previous ocular hypotensive medication.
Methods: This multicenter, open-label, prospective, phase IIIb study included subjects ≥18 years of age with open-
angle glaucoma (OAG) or ocular hypertension (OHT). Eligible subjects had baseline IOP ≥21 mmHg and insufficient 
response to current beta-blocker monotherapy. The primary efficacy analysis (logistic regression) identified predictors 
of a positive response after 12 weeks of latanoprost/timolol FC.
Results: The intent-to-treat (ITT) population included 383 subjects treated with ≥1 drop of FC and having ≥1 follow-up 
IOP assessment. Mean IOP was 22.19 ± 2.16 mmHg at baseline and was reduced by 5.42 ± 2.71 mmHg at study end. In 
all, 325 (84.9%) subjects had a positive response to latanoprost/timolol FC; the response rate was similar across groups: 
OAG (n = 208; 82.7%); OHT (n = 161; 87.6%); OAG+OHT (n = 14; 85.7%). Higher baseline IOP (odds ratio: 1.284; 95% 
confidence interval [CI]: 1.101, 1.497; p = 0.0014) and absence of adverse events (odds ratio: 0.318; 95% CI: 0.161, 0.629; 
p = 0.0010) were significant predictors of positive response. Age, gender, ethnic origin, diagnosis, family history of OAG/
OHT, corneal thickness, and concomitant systemic beta-blocker were not significant predictors of a positive response 
in the ITT analysis. The FC was well tolerated. The most common adverse events were related to the eye and were 
consistent with known adverse events associated with latanoprost and timolol.
Conclusions: These results support the use of latanoprost/timolol FC in patients whose IOP is insufficiently controlled 
on beta-blocker monotherapy. Patients with higher baseline IOP levels and who do not experience adverse events 
while on therapy are most likely to achieve a positive response to latanoprost/timolol FC.
Trial Registration: Study registration number: NCT00230763
Background
Disease progression in patients with open-angle glau-
coma (OAG) or ocular hypertension (OHT) can be
slowed or stopped by reducing intraocular pressure (IOP)
levels though the use of ocular hypotensive agents [1-5].
First-choice options for medical treatment of elevated
IOP levels usually are topical beta-blockers such as
timolol maleate and prostaglandin analogs such as
latanoprost [6]. Many patients require more than one
IOP-lowering drug [5] resulting in complex medication
regimens that may be difficult to maintain and that can
lead to non-compliance [6]. Physicians should try to sim-
plify medication regimens in order to maximize patient
compliance [7-10]. In these cases, combining two medi-
cations into a fixed combination (FC) is preferable to pre-
scribing two individual therapies [6]. Where individual
treatment is available in a FC, ease of use and potential
reduction of side effects argue in favor of their use [6].
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Latanoprost/timolol FC became commercially available
in France in 2002 and is indicated for reduction of IOP in
patients with OAG and OHT who are insufficiently
responsive to monotherapy with topical beta-blockers or
prostaglandin analogs [11]. This FC has been shown to be
effective and well tolerated [12-17]. Given the growing
number of ophthalmic medications available, our goal
was to identify predictors of a positive response (i.e., an
additional l0% IOP reduction) in patients with OAG or
OHT who required a change in their previous ophthalmic
medication and who were switched to latanoprost/
timolol FC.
Methods
Study design
This was a prospective, open-label, multicenter, phase
IIIb study conducted in France between October 8, 2005,
and October 5, 2007 (NCT00230763). The final protocol
and informed consent documents were reviewed and
approved by the Independent Ethics Committee (Comité
Consultatif de Protection des Personnes dans la Recher-
che Biomédicale de Lyon B, France). The study complied
with all International Conference on Harmonization
Good Clinical Practice guidelines and with the Declara-
tion of Helsinki. Written informed consent was obtained
prior to a subject entering the study (i.e., before initiation
of protocol-specified procedures).
Subjects
Male or female subjects ≥18 years of age diagnosed with
OAG or OHT with an IOP ≥21 mmHg were eligible if
they were being treated with an ophthalmic beta-blocker
monotherapy and if, in the investigator's opinion, they
required a change in ocular hypotensive therapy because
of an insufficient response to treatment. Excluded were
those currently treated or treated within the prior month
with any ophthalmic hypotensive agent other than a beta-
blocker; with any contraindication to latanoprost or
timolol including medical conditions that would preclude
use of the study medication; with known intolerance to
benzalkonium chloride or any excipient contained in the
study medication; with severe visual field loss and/or
optic disc damage; who had participated in another clini-
cal trial within the prior 30 days; who had been previously
treated with latanoprost/timolol FC; or who, in the opin-
ion of the investigator, had an ophthalmic or general
medical condition that prevented participation. Also
excluded were women of childbearing potential who were
not using adequate contraceptive methods or who were
pregnant or nursing.
Treatments and assessments
At the baseline visit, demographic data and medical, ocu-
lar, and treatment histories were recorded, and biomi-
croscopy and ophthalmoscopy were performed. Prior to
pupil dilation, best-corrected visual acuity was measured
(Monoyer scale for distant vision and Parinaud scale for
near vision), and IOP was measured by pulse air tonome-
try or calibrated Goldmann applanation tonometry. With
pulse air tonometry, three IOP measurements were per-
formed, and the mean value was used in analyses; with
Goldmann applanation tonometry, only one measure-
ment was required. Both eyes were examined, even if only
one eye was to be treated with latanoprost/timolol FC.
The Glaucoma Symptom Scale (GSS) [18] and a satisfac-
tion questionnaire developed for this study that included
items regarding medication compliance were completed
by the subject. The GSS, a brief, simple, and reliable
instrument, has been found to discriminate well between
individuals with and without glaucoma [18]. The GSS has
been used to evaluate the personal burden of glaucoma in
a variety of settings [19-21].
At the baseline visit, subjects stopped the previous ocu-
lar hypotensive therapy and were given sufficient latano-
prost/timolol FC for the next 4 weeks. Subjects were
instructed to instill the FC in each affected eye once daily
in the evening starting the following day. Approximately 4
weeks postbaseline, subjects returned for an intermediate
study visit at which time IOP was measured prior to pupil
dilation using the method employed at baseline. The sub-
ject completed the GSS and satisfaction/compliance
questionnaire, and physicians assessed the presence of
adverse events and the global response to FC treatment.
Each adverse event whether observed, elicited, or
reported spontaneously was recorded, and the investiga-
tor graded its intensity (mild, moderate, severe) and eval-
uated whether the event was related to the FC. Serious
adverse events were those that resulted in death, that
were life-threatening, that required or prolonged hospi-
talization, that resulted in persistent or significant dis-
ability/incapacity, or that resulted in congenital anomaly/
birth defect. At this intermediate visit, subjects were
given sufficient latanoprost/timolol FC for the next 8
weeks. After 12 weeks of FC therapy, subjects returned
for a final study visit at which time the assessments done
at week 4 were repeated, visual acuity was measured,
ophthalmoscopy and biomicroscopy were performed,
and ophthalmic abnormalities were summarized by
severity.
Endpoints and analyses
The primary efficacy analysis was performed on the
intent-to-treat (ITT) population defined as all subjects
who received at least one dose of latanoprost/timolol FC
and who had at least one on-study IOP evaluation. The
per protocol (PP) population excluded those in the ITT
population with a major protocol deviation. In analyses of
IOP level, visual acuity, and GSS scores, the mean valueSellem et al. BMC Ophthalmology 2010, 10:10
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from both eyes was used if both eyes were treated with
latanoprost/timolol FC; otherwise, only data for the
treated eye were included in analyses. The last observa-
tion carried forward method, using the last available
postbaseline observation, was used to impute missing
continuous data. The safety population included subjects
who received at least one dose of latanoprost/timolol FC.
The primary efficacy endpoint was a positive response
to latanoprost/timolol FC defined as an IOP reduction
>10% from baseline after 12 weeks of treatment. A step-
wise logistic regression model was used to evaluate asso-
ciations between possible baseline and on-treatment
predictors of a positive response. Potential predictors
included age, gender, ethnic origin, family history of
OAG, family history of OHT, concomitant systemic treat-
ment with beta-blockers, diagnosis (OAG/OHT/OAG in
one eye and OHT in the other eye), IOP at baseline, cor-
neal thickness, compliance, and presence/absence of
adverse events as well as interactions between gender and
diagnosis. Subjects with missing values for predictors
were excluded from analyses of affected variables. Vari-
ables with ≥20% missing data were excluded. Covariates
were included in the stepwise model with the significance
level for entry fixed at 5% and the significance level for
retention fixed at 10%. P-values and 95% confidence
intervals (CIs) for the odds ratios were calculated. In case
of a difference of >10% between the number of subjects in
the ITT and PP populations, a secondary analysis for the
primary efficacy endpoint was conducted on the PP pop-
ulation.
Secondary efficacy endpoints were summarized for the
ITT population overall and stratified by gender and diag-
nosis. Endpoints included absolute and relative IOP
changes from baseline to week 12; percentages of subjects
achieving a ≥5% or ≥15% IOP reduction from baseline at
week 12; percentages of subjects achieving IOP levels of
<18 and <16 mmHg at week 12; absolute and relative
visual acuity changes from baseline to week 12; absolute
changes in GSS scores (total score, non-visual symptom
score, and visual symptom score) from baseline to weeks
4 and 12; subject satisfaction with FC treatment at base-
line and weeks 4 and 12; and investigator's global assess-
ment of response to FC treatment at weeks 4 and 12. The
significance of potential predictors of achieving specified
percentage IOP reductions and of reaching specified IOP
levels at week 12 was analyzed by stepwise logistic regres-
sion models. The same 11 covariates that were included
in the primary analysis were evaluated. Absolute and rela-
tive IOP changes, visual acuity changes, and changes in
GSS scores were evaluated using analysis of covariance
(ANCOVA) models that included the relevant baseline
score as a covariate; adjusted (least square) and unad-
justed means were calculated, and pairwise differences
between etiologies were summarized along with standard
errors, p-values, and 95% CIs. GSS scores were trans-
formed to a scale of 0 (maximum complaint) to 100 (no
complaint), where transformed score = score*25. Data
concerning patient satisfaction/compliance and investi-
gators' assessments of global response to treatment were
tabulated and summarized. At baseline, the number of
subjects on each type of beta-blocker was summarized as
were IOP levels prior to beta-blocker initiation (if avail-
able), beta-blocker treatment duration, and reason for
treatment change (investigator judgment).
Data reflecting systemic and ophthalmic adverse events
were tabulated and summarized for the safety population.
Adverse events were classified by System Organ Class
and preferred term according to the Medical Dictionary
for Regulatory Activities (MedDRA) Version 11.1. Per-
centages of subjects with relevant ophthalmic abnormali-
ties at week 12 were compared across etiologies using the
chi-square or Fisher's exact test.
The sample size calculation was based on the assump-
tions that 20% to 50% of subjects would achieve IOP
reduction >10% after 12 weeks of latanoprost/timolol FC
and that the same percentage of subjects was exposed to
the predictive factor identified (e.g., age above n years).
With an odds ratio = 2, a significance level = 5%, and
power = 80%, 395 subjects were required.
Results
One hundred and twenty-one centers screened 395 sub-
jects and assigned all of them to latanoprost/timolol FC
(Figure 1). In all, 391 subjects received at least one dose of
the FC and were included in the safety population; 344
completed the study while 21 discontinued for reasons
related to the study drug and 26 discontinued for reasons
unrelated to latanoprost/timolol FC. The ITT population
included 383 subjects, and the PP population included
the 316 subjects without a major protocol deviation. Of
the 98 major protocol deviations recorded in 70 subjects,
67 of whom were in the ITT population, most related to
noncompliance with inclusion/exclusion criteria (n = 50),
not using study drug at the time of IOP assessment (n =
20), or use of commercial latanoprost/timolol FC during
the study (n = 20).
The treatment group, which was overwhelmingly Cau-
casian, included 182 males and 209 females with a mean
age of 63.0 years (Table 1). At screening, the majority of
subjects were diagnosed with OAG, more than half had at
least one concomitant condition at screening, and most
were being treated with timolol (206/383, 53.8%) or carte-
olol (144/383, 37.6%). Subjects had been on the screening
therapy for an average of 2.5 years and had a mean IOP of
approximately 24 mmHg in both eyes prior to initiating
beta-blocker monotherapy. Insufficient efficacy was the
primary reason given by investigators for switching to
latanoprost/timolol FC. The median duration of latano-Sellem et al. BMC Ophthalmology 2010, 10:10
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prost/timolol FC treatment was 89.0 days (range, 3 to 183
days).
At week 12, a positive response (IOP reduction >10%
from baseline) to latanoprost/timolol FC was obtained in
325/383 (84.9%) subjects in the ITT population (Table 2).
No clinically significant difference in responder rates was
noted with regard to diagnosis or gender. Of the 10
potential predictors included into the logistic regression
analysis, two were associated with a positive IOP
response: higher baseline IOP (parameter estimate, 0.25;
odds ratio [95% CI], 1.284 [1.101, 1.497]; p = 0.0014) and
absence of adverse events (parameter estimate, -1.15;
odds ratio [95% CI], 0.318 [0.161, 0.629]; p = 0.0010).
(Note that the eleventh variable, compliance, was not
included in this analysis because data were missing for
≥20% of subjects.) In the PP population, 288/316 (91.1%)
subjects had a positive response. In this analysis popula-
tion, higher baseline IOP but not absence of adverse
events was significantly associated with a positive
response to latanoprost/timolol FC; age was included in
the model (p = 0.0332), but the odds ratio was close to 1
(1.045), suggesting that age had little clinical relevance.
The relative overall mean IOP reduction from baseline
to week 12 of 24.10 ± 11.35% reflected a mean absolute
change of -5.42 ± 2.71 mmHg from the baseline mean of
22.19 ± 2.16 mmHg (Table 3). The hypotensive effect was
observed as soon as the week 4 visit when the mean IOP
level was 16.98 ± 2.46 mmHg. Absolute and relative IOP
changes were similar across diagnosis and gender groups.
Results of ANCOVA confirmed that diagnosis did not
significantly influence IOP changes.
Reductions in IOP from baseline to week 12 of at least
5% or 15% were obtained in 339/383 (88.5%) and 298/383
(77.8%) of subjects, respectively (Table 4). Thus, 298 of
Figure 1 Subject disposition. FC = fixed combination.
Screened
N = 395
Assigned to
FC latanoprost/timolol
N = 395
Treated
N = 391
Not treated
N = 4
Related to FC
latanoprost/timolol
• Adverse event,  
N = 20
￿ Lack of efficacy, 
N = 1
Discontinued
study
N = 47
Completed
study
N = 344
Not related to FC
latanoprost/timolol
￿ Adverse event,  
N = 2
￿ Lost to follow-up,
N = 1
￿ Withdrew consent,
N = 8 
￿ Other,                   
N = 15
Table 1: Demographic and baseline characteristics of 
subjects assigned to treatment, N = 391
Gender, n (%)
Male 182 (46.5)
Female 209 (53.5)
Age, years
Mean ± SD 63.0 ± 11.8
Range 18 - 87
Race, n (%)
Caucasian 381 (97.4)
Other 10 (2.6)
Primary diagnosis*
OAG, n 227
Time since 
diagnosis, years, 
Mean (Range)
5.0 (0.0 - 25.2)
OHT, n 181
Time since 
diagnosis, years, 
Mean (Range)
4.1 (0.0 - 24.5)
Family history of OAG or OHT,
n (%)†
Yes 208 (54.3)
No 162 (42.3)
Unknown/not recorded 13 (3.4)
Central corneal thickness†§
Mean ± SD 559.0 ± 37.6
Range 450 - 662
Concomitant conditions, n 
(%)
Any such condition 217 (55.5)
Vascular disorder 126 (32.2)
Ophthalmic disease 116 (29.7)
Metabolism and 
nutrition disorder
102 (26.1)
*Seventeen subjects had different diagnoses between eyes.
†Intent-to-treat population: n = 383.
§Data not recorded for 17 subjects.
OAG = open-angle glaucoma; OHT = ocular hypertension; SD = 
standard deviation.Sellem et al. BMC Ophthalmology 2010, 10:10
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325 responders (91.7%) also achieved a 15% or greater
decrease in IOP. Logistic regression analyses revealed
that, as for the primary endpoint, two factors predicted a
reduction in IOP of ≥5% and ≥15%: higher IOP at baseline
and absence of adverse events (p = 0.02 for all). Again,
neither diagnosis nor gender was a significant predictor
of response. An IOP level <18 mmHg was achieved by
255/383 (66.6%) subjects, and an IOP <16 mmHg was
noted in 128/383 (33.4%; Table 4). Lower baseline IOP
and thinner corneas were significant predictors of both
IOP <16 mmHg and <18 mmHg; absence of adverse
events was significantly associated with reaching an IOP
of <18 mmHg.
On average, subjects had good visual function at base-
line (Monoyer scale, 8.50 ± 1.99; Parinaud scale, 2.30 ±
1.18) and experienced little change by week 12 (change in
Monoyer scale, 0.03 ± 0.80; change in Parinaud scale, -
0.05 ± 0.71). No clinically relevant changes in glaucoma
symptoms were observed between baseline and week 12
as reflected by minimal changes in the global GSS score
as well as by the non-visual and visual GSS subscale
scores (Table 5).
Table 2: Subjects achieving a positive response to latanoprost/timolol FC* (ITT population)
All
N = 383
OAG
N = 208
OHT
N = 161
Both
N = 14
Positive response, 
n (%)
325 (84.9) 172 (82.7) 141 (87.6) 12 (85.7)
Male, N = 179 156 (87.2)
Female, N = 204 169 (82.8)
*Positive response = >10% IOP reduction from baseline to week 12.
Both = both OAG and OHT; FC = fixed combination; IOP = intraocular pressure; ITT = intent-to-treat population; OAG = open-angle glaucoma; 
OHT = ocular hypertension.
Table 3: IOP changes from baseline to week 12 by diagnosis and gender, mean ± SD (ITT population)
Diagnosis
IOP All
N = 383
OAG
N = 208
OHT
N = 161
Both
N = 14
Baseline, mmHg 22.19 ± 2.16 21.95 ± 2.27 22.40 ± 1.97 23.36 ± 2.19
Week 12, mmHg 16.77 ± 2.62 16.61 ± 2.77 17.00 ± 2.48 16.64 ± 1.67
Change from baseline 
to week 12, mmHg
-5.42 ± 2.71 -5.34 ± 2.76 -5.40 ± 2.60 -6.71 ± 2.95
Change from baseline 
to week 12, %
-24.10 ± 11.35 -24.06 ± 11.70 -23.82 ± 10.92 -28.07 ± 10.86
Gender
Male
N = 179
Female
N = 204
Baseline, mmHg 22.29 ± 2.13 22.10 ± 2.20
Week 12, mmHg 16.53 ± 2.55 16.99 ± 2.67
Change from baseline 
to week 12, mmHg
-5.76 ± 2.77 -5.11 ± 2.62
Change from baseline 
to week 12, %
-25.51 ± 11.38 -22.87 ± 11.20
Both = OAG and OHT; IOP = intraocular pressure; ITT = intent-to-treat population;
OAG = open-angle glaucoma; OHT = ocular hypertension; SD = standard deviation.Sellem et al. BMC Ophthalmology 2010, 10:10
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At the end of the study, 292/319 (91.5%) subjects
responding to the satisfaction/compliance questionnaire
indicated that they were "very satisfied" or "satisfied" with
their ocular hypotensive therapy, an improvement from
the 246/313 (78.6%) expressing this level of satisfaction
with the monotherapy administered at the time of the
switch to latanoprost/timolol FC. Subject-reported medi-
cation compliance (instilling drops "every day without
exception") also improved from 65% under previous beta-
blocker monotherapy to 81% with latanoprost/timolol
FC. Nearly 90% of investigators rated the FC as "effective"
at the end of the study.
No death occurred among study participants. Five sub-
jects experienced a total of six treatment-emergent seri-
ous adverse events, none of which was considered by
investigators to be treatment-related. Among the 391
subjects in the safety population, 89 (22.8%) experienced
at least one all causality adverse event, and 22 (5.6%) dis-
continued due to an adverse event (Table 6). Eleven all
causality adverse events were considered to be severe in
intensity. Sixty subjects (15.3%) experienced at least one
treatment-related adverse event; such events led to study
discontinuation for 20 (5.1%) subjects. "Eye disorders"
was the System Organ Class most frequently involved,
and the most commonly reported treatment-related ocu-
lar adverse events were eye irritation (n = 5), hyperemia,
(n = 4), dryness (n = 4), pruritis (n = 3), and conjunctivitis
(n = 3). The incidence of ophthalmic abnormalities was
similar at baseline (201/383 [52.5%]) and week 12 (195/
383 [50.9%]) but was significantly greater at the end of the
study among subjects with OAG versus OHT (124/195
[63.6%] versus 68/155 [43.9%], respectively; p < 0.001).
Discussion
The goal of this 12-week, prospective, open-label, multi-
center study was to identify predictors of a positive
response, defined as an additional l0% IOP reduction, to
latanoprost/timolol FC in patients with OAG or OHT
whose IOP was insufficiently controlled on beta-blocker
monotherapy and who required a change in their previ-
ous ophthalmic medication. A positive response was
observed in 84.9% subjects in the ITT population, and
patients most likely to achieve such a response were those
with higher baseline IOP levels and those who did not
experience adverse events while on treatment. Other fac-
tors tested, including age, gender, ethnic origin, diagno-
sis, family history, corneal thickness, and concomitant
use of a systemic beta-blocker, were not significant pre-
Table 4: Subjects achieving prespecified IOP outcomes by diagnosis and gender, n (%) (ITT population)
Diagnosis
Patients with: All
N = 383
OAG
N = 208
OHT
N = 161
Both
N = 14
≥5% IOP reduction from 
baseline to week 12
339 (88.5) 182 (87.5) 145 (90.1) 12 (85.7)
≥15% IOP reduction from 
baseline to week 12
298 (77.8) 156 (75.0) 131 (81.4) 11 (78.6)
IOP <16 mmHg at week 12 128 (33.4) 76 (36.5) 49 (30.4) 3 (21.4)
IOP <18 mmHg at week 12 255 (66.6) 138 (66.3) 107 (66.5) 10 (71.4)
Gender
Male
N = 179
Female
N = 204
≥5% IOP reduction from 
baseline to week 12
160 (89.4) 179 (87.7)
≥15% IOP reduction from 
baseline to week 12
146 (81.6) 152 (74.5)
IOP <16 mmHg at week 12 64 (35.8) 64 (31.4)
IOP <18 mmHg at week 12 126 (70.4) 129 (63.2)
Both = OAG and OHT; IOP = intraocular pressure; ITT = intent-to-treat population;
OAG = open-angle glaucoma; OHT = ocular hypertension.Sellem et al. BMC Ophthalmology 2010, 10:10
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dictors of a positive response. However, in the PP popula-
t i o n  ( w h i c h  i n c l u d e d  o n l y  p a t i e n t s  w i t h o u t  a  m a j o r
protocol violation), age, but not absence of adverse
events, was a significant predictor of positive response.
The predictive power of initial IOP, absence of adverse
events, and age with regard to IOP reduction parallels
results of previous studies. Higher baseline IOP levels
have been associated with greater IOP reductions, due in
part to regression to the mean [22-26]. Negative associa-
tions have been found between medication-related
adverse events and both compliance [7,27] and persis-
tence [28]; it is intuitive that patients who do not take
their ocular hypotensive medication as prescribed cannot
obtain their full IOP-lowering benefit. Finally, older age
has been identified as a risk factor for progression of
glaucoma to blindness [4,29-31].
The effectiveness of latanoprost/timolol FC in reducing
IOP levels has been demonstrated in randomized, dou-
ble-masked, controlled clinical trials [12-17], and switch
studies such as ours are not appropriate for comparing
therapies with regard to efficacy. Compared with other
studies with similar designs, it is notable that the mean
IOP reduction of 5.4 mmHg over 12 weeks was greater
than reductions reported previously [32,33]. Thus, an
average IOP reduction of 3.7 mmHg (from 21.6 to 17.9
mmHg) in 2 months was reported for 53 patients
switched from timolol monotherapy to latanoprost/
timolol FC [32]. In a study that monitored changes in IOP
during the first 6 months following a switch to the FC,
Dunker et al. [33] found statistically significant mean IOP
reductions of 3.3 mmHg among 902 OAG patients and
3.4 mmHg in 42 patients with OHT.
Table 5: Glaucoma Symptom Scale (GSS) scores at baseline and week 12 by diagnosis and gender, mean ± SD (ITT 
population)
Diagnosis
All
N = 383
OAG
N = 208
OHT
N = 161
Both
N = 14
Global GSS score
Baseline 86.15 ± 15.73 84.99 ± 15.89 87.29 ± 15.54 89.41 ± 15.67
Week 12 88.49 ± 14.32 86.81 ± 15.91 90.19 ± 12.50 91.59 ± 8.50
Non-visual GSS score
Baseline 84.60 ± 17.09 84.70 ± 16.14 84.34 ± 18.04 86.11 ± 20.52
Week 12 86.78 ± 15.40 84.74 ± 17.05 89.08 ± 12.95 88.10 ± 14.88
Visual GSS score
Baseline 87.76 ± 18.46 85.97 ± 19.95 89.54 ± 16.81 92.79 ± 11.08
Week 12 89.76 ± 17.26 88.33 ± 19.18 91.06 ± 15.19 94.64 ± 7.70
Gender
Male
N = 179
Female
N = 204
Global GSS score
Baseline 87.28 ± 15.24 85.19 ± 16.13
Week 12 90.05 ± 13.96 87.08 ± 14.55
Non-visual GSS score
Baseline 86.52 ± 15.77 82.95 ± 18.02
Week 12 88.81 ± 14.17 84.90 ± 16.27
Visual GSS score
Baseline 88.15 ± 18.29 87.43 ± 18.64
Week 12 90.81 ± 16.40 88.83 ± 17.98
Both = OAG and OHT; ITT = intent-to-treat population; OAG = open-angle glaucoma;
OHT = ocular hypertension; SD = standard deviation.Sellem et al. BMC Ophthalmology 2010, 10:10
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An unknown proportion of IOP reductions reported in
switch studies may have been attributable to the Haw-
thorne effect, the tendency for subjects to improve in
response to the fact of being studied rather than in
response to the experimental change [34,35]. Findings of
six studies [36-41] in which one group or eye continued
on the baseline ocular hypotensive therapy while the
other group or eye switched to another agent for periods
ranging from 21 days to 6 months are inconsistent with
regard to the potential magnitude of such an effect. Effect
sizes ranged from -0.37 mmHg in 115 patients continued
for 6 months on dual therapy that included a beta-blocker
[40] to -3.1 mmHg in five patients continued for 12 weeks
on timolol [38]. Mean IOP reductions in the control
group in each of these six studies were substantially
smaller than the -5.4 mmHg mean change from baseline
to week 12 observed herein.
No change in visual acuity was noted at the end of this
relatively short-term study in these patients with good
vision at baseline, and no clinically relevant changes in
gla uc o ma  sym pt o m s based on G SS  sc or es  we r e  f ound.
The latter result may reflect the fact that the study popu-
lation presented at baseline with GSS scores similar to
those observed in the reference group (without glau-
coma) of the study that assessed the validity and reliabil-
ity of the GSS [18]. In addition, the GSS may not be
sensitive enough to assess short-term changes in symp-
toms in our patient group. The authors noted that the
population used to test the validity and reliability of the
GSS "... may not accurately represent a community-based
setting, where populations of persons with glaucoma are
likely to have milder disease and/or are likely to receive
treatments" [18].
Table 6: Adverse events by body system, n (%)
All causality adverse events
N = 391
Treatment-related adverse events
N = 391
Any adverse event 89 (22.8) 60 (15.3)
Discontinued due to adverse event 22 (5.6) 20 (5.1)
System Organ Class
Cardiac disorders 3 (0.8) 2 (0.5)
Ear and labyrinth disorders 4 (1.0) 3 (0.8)
Eye disorders 40 (10.2) 34 (8.7)
Gastrointestinal disorders 6 (1.5) 3 (0.8)
General disorders and administration 
site conditions
11 (2.8) 8 (2.0)
Immune system disorders 2 (0.5) 2 (0.5)
Infections and infestations 8 (2.0) 1 (0.3)
Injury, poisoning, and procedural 
complications
2 (0.5) 1 (0.3)
Investigations 2 (0.5) 2 (0.5)
Metabolism and nutrition disorders 1 (0.3) 1 (0.3)
Musculoskeletal and connective 
tissue disorders
2 (0.5) -
Nervous system disorders 12 (3.1) 8 (2.0)
Psychiatric disorders 8 (2.0) 6 (1.5)
Reproductive system and breast 
disorders
1 (0.3) 1 (0.3)
Respiratory, thoracic, and mediastinal 
disorders
4 (1.0) 3 (0.8)
Skin and subcutaneous tissue 
disorders
10 (2.6) 9 (2.3)
Surgical and medical procedures 2 (0.5) -
Vascular disorders 6 (1.5) 2 (0.5)Sellem et al. BMC Ophthalmology 2010, 10:10
http://www.biomedcentral.com/1471-2415/10/10
Page 9 of 10
As has been reported previously [12-17], the FC was
well tolerated. The most common adverse events were
related to the eye and were consistent with known
adverse events associated with latanoprost or timolol.
The six serious adverse events were not considered to be
related to study treatment.
While this study's open-label observational design may
better reflect actual clinical practice than controlled clini-
cal trials, the study had several limitations. In particular,
not all of the investigators used applanation tonometry to
measure IOP levels, and because the method of IOP mea-
surement was not always documented, we could not ana-
lyze IOP changes stratified by tonometry type. Although
every effort was made to ensure consistency of proce-
dures and data recording across centers, the extent of
variation among practices is unknown. The 12-week fol-
l o w - u p  p e r i o d  w a s  n o t  s u f f i c i e n t  t o  d e t e c t  l o n g - t e r m
changes in visual acuity or GSS scores. Finally, we consid-
ered a favorable response to the FC to be an additional
10% IOP reduction, an arbitrary cutoff point. Regression
to the mean [26] may have accounted for reductions in
some of the 84.9% of subjects counted as responders, but
it is notable that 77.8% of subjects recorded IOP reduc-
tions of at least 15% from baseline to week 12.
Conclusions
Reducing IOP levels slows down disease progression in
glaucoma patients [1-4] and delays progression to glau-
coma in OHT patients [5]. Our findings support the use
of latanoprost/timolol FC in routine clinical practice in
patients whose IOP is insufficiently controlled on beta-
blocker monotherapy. Patients with higher baseline IOP
levels and who do not experience adverse events are most
likely to achieve a positive response to the FC.
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